SCHEMBL434736

SCHEMBL434736

Cc1cccc(C(=NO)c2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
HPGD P15428 2/20 0.52
GFER P55789 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 4/20 0.47
PARP1 P09874 1/20 0.47
MAPT P10636 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
XBP1 P17861 1/20 0.44
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
ACHE P22303 1/20 0.42
CTSL P07711 2/20 0.42
CTSK P43235 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14416770 1.00 ALDH1A1 (0.52) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL434734 1.00 ALDH1A1 (0.52) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL10887870 0.81 ALDH1A1 (0.62) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL10887872 0.81 ALDH1A1 (0.62) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL14416989 0.81 ALDH1A1 (0.62) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL273196 0.80 HPGD (0.64) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL27961040 0.80 HPGD (0.64) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL4401103 0.78 ESR2 (0.59) ALDH1A1SMN1; SMN2POLBPARP1MAPT
Water SCHEMBL9518556 0.78 HPGD (0.61) ALDH1A1HPGDGFERSMN1; SMN2POLB
SCHEMBL28341134 0.78 HPGD (0.68) ALDH1A1HPGDGFERSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 ALDH1A1 2410/4885HPGD 1276/4885GFER 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.